Tesla
TSLA
Netflix
NFLX
Disney
DIS
4
Cisco
CSCO
5
Meta Platforms
META
US Stock MarketDetailed Quotes
FATE Fate Therapeutics
- 1.170
- -0.080-6.40%
Close Apr 29 16:00 ET
134.09MMarket Cap-0.71P/E (TTM)
1.270High1.150Low1.37MVolume1.250Open1.250Pre Close1.63MTurnover1.37%Turnover RatioLossP/E (Static)114.60MShares5.92052wk High0.42P/B117.11MFloat Cap0.66152wk Low--Dividend TTM100.10MShs Float121.160Historical High--Div YieldTTM9.60%Amplitude0.661Historical Low1.187Avg Price1Lot Size
Market Insights
U.S Tech Companies U.S Tech Companies
U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data. U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data.
Unlock Now
Discussing
FOMC holds rates amid heightened uncertainty: Where will US stocks head next?
🎙️Discussion 1. With the Fed highlighting "elevated uncertainty", are you prioritizing rate projections or near-term economic data for ma
Moo Live
Mar 20 02:25
FOMC Press Conference, March 19, 2025
Fate Therapeutics Stock Forum
Game-Changing FDA Status: Fate's Off-the-Shelf Lupus Treatment Speeds Toward Approval
Fate Therapeutics Receives Regenerative Medicine Advanced Therapy (Rmat) Designation From FDA for FT819 to Treat Moderate to Severe Systemic Lupus Erythematosus (Sle)
Fate Therapeutics Receives Regenerative Medicine Advanced Therapy (RMAT) Designation from FDA for FT819 to Treat Moderate to Severe Systemic Lupus Erythematosus (SLE)
Monday, 14th April at 8:00 am
– Recognizes potential of off-the-shelf CAR T-cell therapy to address significant unmet need and enables increased dialogue with FDA throughout the development process
– RMAT review by FDA included initial clinical safety and activity data from ongoing Phase 1 study...
finally
No comment yet